Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
iPark Institute is looking to set up an operating base in South Korea in two years and forge a partnership with the country’s government in a bid to attract local companies to a science park it manages, dubbed Shonan iPark,…
To read the full story
Related Article
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- iPark Institute Takes Over Shonan iPark Operations from Takeda to Boost Neutrality, Collaborations
April 14, 2023
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
BUSINESS
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
- Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
- Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
- Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…